

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035055 A1

(51) International Patent Classification⁷: **A61K 31/277**,
31/4453, 31/4015, 31/40, C07D 295/14, 295/12, 207/12,
205/04, C07K 5/06, 5/02, C07C 255/60

RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UZ, VC, VN, YU, ZA, ZM.

(21) International Application Number: PCT/US02/33869

(22) International Filing Date: 23 October 2002 (23.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/343,065 25 October 2001 (25.10.2001) US

(71) Applicant: SCHERING CORPORATION [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033-0530
(US).

(72) Inventors: PALANI, Anandan; 25 Reinhart Way, Bridge-
water, NJ 08807 (US). SHAPIRO, Sherry, A.; 574 East
Road, Belford, NJ 07718 (US). MC BRIAR, Mark, D.;
1155 Monroe Drive, Stewartville, NJ 08886 (US). SU,
Jing; 1398 Graymill Drive, Scotch Plains, NJ 07076 (US).

(74) Agent: LEE, William, Y.; Schering-Plough Corporation,
Patent Department - K-6-1 1990, 2000 Galloping Hill
Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ,
DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV,
MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT,

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:



- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY



(57) Abstract: The present invention discloses compounds of formula (I) and (II), which are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat

obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

WO 03/035055 A1

CN01510K PCT

MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY

5

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/343,065 filed on October 25, 2001.

10

FIELD OF THE INVENTION

This invention relates to antagonists of melanin-concentrating hormone (MCH) and their use in the treatment of obesity, eating disorders and diabetes, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds.

15

BACKGROUND OF THE INVENTION

MCH, a cyclic peptide, was first identified over a decade ago in teleost fish where it appears to regulate color change. More recently, MCH has been the subject of investigation for its possible role as a regulator of eating behavior in mammals. As reported by Shimada et al., *Nature*, Vol. 396 (17 Dec. 1998), pp. 670-673, MCH-deficient mice have reduced body weight and leanness due to hypophagia (reduced feeding). In view of their findings, it was suggested that antagonists of MCH action may be effective for the treatment of obesity. U.S. Patent No. 5,908,830 discloses a combination therapy for the treatment of diabetes or obesity involving the administration of a metabolic rate increasing agent and a feeding behavior modifying agent, an example of the latter being an MCH antagonist.

20

25

US Patent 6,245,746, which issued, June 12, 2001, discloses amide compounds which have efflux pump inhibitor activity related to the field of anti-microbial agents.


30

SUMMARY OF THE INVENTION

In one embodiment, this invention provides novel compounds having MCH antagonist activity. These compounds are represented by structural formula I:

35

- 2 -



formula I

or a pharmaceutically acceptable salt or solvate of said compound, wherein:

X is a single bond, -C-, -CH- or alkylene, and when X is a single bond, R⁶ is absent and the carbon atom marked 1 is directly attached to N of N-Y;

Y is a single bond, -C-, -CH- or alkylene, and when Y is a single bond, R⁵ is absent and the carbon atom marked 7 is directly attached to N of N-X;


R¹ is aryl or heteroaryl, wherein each of said aryl or heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CN, CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R² is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R³ is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R⁴ is selected from the group consisting of -alkylene-N(R⁷)₂, -N(H)alkylene-N(R⁷)₂, -O-alkylene-N(R⁷)₂,

- 3 -



and

wherein each R^7 in said $-N(R^7)_2$, can be the same or different, each R^7 is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R^7 can be joined together and with the nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring;

p is 0 to 5 and when p is >1, the number of p moieties can be the same or different;

R^5 is H or 1 or 2 substituents independently selected from alkyl or cycloalkyl;

R^6 is H or 1 or 2 substituents independently selected from alkyl or cycloalkyl;

and


R^8 is H, OH, alkoxy, alkyl, cycloalkyl, aryl, $-N(H)R^7$, $-N(H)C(O)alkyl$, $-N(H)C(O)aryl$, $-N(H)C(O)N(H)alkyl$, $-N(H)C(O)N(H)aryl$, $-N(H)S(O_2)alkyl$ or $-N(H)S(O_2)aryl$;

- 4 -

with the proviso that the carbons shown marked 1 and 6 on the aromatic ring, along with X-R⁶, can optionally form a 4 to 8 membered ring system.

A preferred group of compounds are those listed below in the Detailed Description as described in Formulae Ia, Ib and Ic.

5 The present invention also relates to compounds represented by structural formula II:



formula II

or a pharmaceutically acceptable salt or solvate of said compound, wherein:

10 Y is a single bond, -C-, -CH- or alkylene, and when Y is a single bond, R⁵ is absent and the carbon atom marked 7 is directly attached to N of N-X;

Z is a single bond, -C-, -CH- or alkylene, and when Z is a single bond, R⁶ is absent and the carbon atom marked 1 is directly attached to the carbon atom marked 8;







15 R¹ is aryl or heteroaryl, wherein each of said aryl or heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CN, CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

20 R² is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

25 R³ is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl,

- 5 -

haloalkoxy, alkoxy and OH;

 R^5 is H or 1 or 2 substituents independently selected from alkyl or cycloalkyl; R^6 is H or 1 or 2 substituents independently selected from alkyl or cycloalkyl; R^{10} is selected from the group consisting -alkylene(R^7)₂,

and

wherein each R^7 in said $\text{---N(R}^7\text{)}_2$, can be the same or different, each R^7 is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R^7 can be joined together and with the nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring;

 n is 0 or 1;

p is 0 to 5 and when p is >1, the number of p moieties can be the same or different;

and

- 6 -

R^8 is H, OH, alkoxy, alkyl, cycloalkyl, aryl, $-N(H)R^7$, $-N(H)C(O)alkyl$, $-N(H)C(O)aryl$, $-N(H)C(O)N(H)alkyl$, $-N(H)C(O)N(H)aryl$, $-N(H)S(O_2)alkyl$ or $-N(H)S(O_2)aryl$;

with the proviso that the carbons shown marked 1 and 6 on the aromatic ring,
5 along with $X-R^6$, can optionally form a 4 to 8 membered ring system.


The compounds of formulae I and II can be useful as MCH receptor antagonists and can be useful in the treatment of metabolic disorders such as obesity and eating disorders such as hyperphagia.

Another embodiment of this invention is directed to pharmaceutical
10 compositions for the treatment of obesity which comprise an obesity treating amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound, and a pharmaceutically acceptable carrier therefor.

DETAILED DESCRIPTION

15 In one embodiment, the present invention discloses MCH receptor antagonists represented by structural formulae I and II or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are described above.

A preferred embodiment is a compound of formula Ia:



formula Ia

or a pharmaceutically acceptable salt or solvate of said compound, wherein:

q is 0 to 5 and when q is >1 , the number of q moieties can be the same or different;

X is $-CH-$ or alkylene;

25 Y is a CH_2 ;

R^2 is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the


- 7 -

group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R^3 is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF_3 , halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R^4 is -alkylene- $N(R^7)_2$, wherein the two R^7 moieties can be the same or different, each R^7 is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R^7 can be joined together and with the nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring, or

R^4 is selected from




R^5 and R^6 can be the same or different, and are independently H or alkyl;

R^8 is H, OH, alkoxy, alkyl, cycloalkyl, aryl, -N(H) R^7 , -N(H)C(O)alkyl, -N(H)C(O)N(H)alkyl or -N(H)S(O₂)alkyl;

and

R^9 is alkyl, F, Cl, Br, I, NO₂, C(O)NH₂, C(O)N(H)R or N(H)C(O)R, wherein R is alkyl, OCF₃, CF₃ or CN.

Another preferred embodiment is a compound of formula Ib:



- 8 -

formula Ib

or a pharmaceutically acceptable salt or solvate of said compound, wherein:


X is an alkylene group;

R¹ is 3-cyanophenyl;

5 R² is H;

R³ is a phenyl, wherein said phenyl is substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;


10 R⁴ is -alkylene-N(R⁷)₂, wherein the two R⁷ moieties can be the same or different, each R⁷ is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R⁷ can be joined together and with the nitrogen to which they are attached to form a 3 to 7-membered heterocycl ring; or R⁴ is selected from



and

20 R⁸ is H, alkyl, cycloalkyl, aryl, -N(H)alkyl, -N(H)aryl, OH, alkoxy, -N(H)C(O)alkyl, -N(H)C(O)N(H)alkyl or -N(H)S(O₂)alkyl.

Another preferred embodiment is a compound of formula Ic:



methyl group is (S), (R) or racemic

- 9 -

formula Ic


or a pharmaceutically acceptable salt or solvate of said compound, wherein:

R^1 is 3-cyanophenyl;

R^2 is H;

5 R^3 is a phenyl, wherein said phenyl is substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF_3 , halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;


10 R^4 is $-alkylene-N(R^7)_2$, wherein the two R^7 moieties can be the same or different, each R^7 is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R^7 can be joined together and with the
15 nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring; or R^4 is selected from



and

20 R^8 is H, alkyl, cycloalkyl, aryl, $-N(H)alkyl$, $-N(H)aryl$, OH, alkoxy, $-N(H)C(O)alkyl$, $-N(H)C(O)N(H)alkyl$ or $-N(H)S(O_2)alkyl$.

A further preferred embodiment is a compound of formula IIa:



- 10 -

formula IIa

or a pharmaceutically acceptable salt or solvate of said compound, wherein:




R^1 is 3-cyanophenyl;

R^2 is H;

5 R^3 is a phenyl, wherein said phenyl is substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF_3 , halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

10 R^8 is H, OH, alkyl, cycloalkyl, aryl, -N(H)alkyl, -N(H)aryl, -N(H)C(O)alkyl, N(H)C(O)N(H)alkyl or -N(H)S(O₂)alkyl;
and

R^{10} is selected from the group consisting -alkylene(R^7)₂,



15 wherein the two R^7 moieties can be the same or different, each R^7 is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R^7 can be joined together and with the nitrogen to which they are
20 attached to form a 3 to 7-membered heterocyclyl ring.

A particularly preferred group of compounds are shown in Examples 1-65 and Tables 1, 2 and 3 of the Experimental Examples.

The present antagonists of formula I or II can be administered as racemic mixtures or enantiomerically pure compounds.

25 As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

"Patient" includes both human and animals.

- 11 -

"Mammal" means humans and other mammalian animals.

"Alkyl" means an aliphatic hydrocarbon group, which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred
5 alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain, which may be straight or branched. The term "substituted alkyl" means that the alkyl group may be substituted by one or more substituents which
10 may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)₂, carboxy and -C(O)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.

"Aryl" means an aromatic monocyclic or multicyclic ring system comprising
15 about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally independently substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.

"Heteroaryl" means an aromatic monocyclic or multicyclic ring system
20 comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as
25 defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least one nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl,
30 furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalyl, phthalazinyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like.

- 12 -

"Aralkyl" or "arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.

5 "Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 3 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 3 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples
10 of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like.

"Cycloalkylalkyl" means a cycloalkylalkyl group. Non-limiting examples of suitable cycloalkylalkyl groups include cyclopropylmethyl and cyclopropylethyl. The
15 bond to the parent moiety is through the alkyl.

"Heterocyclalkyl" means a heterocyclalkyl group. Non-limiting examples of suitable heterocyclalkyl groups include piperidinylmethyl and piperazinylmethyl. The bond to the parent moiety is through the alkyl.

"Halogen" means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine or bromine, and more preferred are fluorine and chlorine.
20

"Halo" means fluoro, chloro, bromo, or iodo groups. Preferred are fluoro, chloro or bromo, and more preferred are fluoro and chloro.

"Ring system substituent" means a substituent attached to an aromatic or non-aromatic ring system, which, for example, replaces an available hydrogen on the ring
25 system. Ring system substituents may be the same or different, each being independently selected from the group consisting of aralkyl, heteroaralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio,
30 cycloalkyl, heterocyclalkyl, Y_1Y_2N- , Y_1Y_2N -alkyl-, $Y_1Y_2NC(O)-$ and $Y_1Y_2NSO_2-$, wherein Y_1 and Y_2 may be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, and aralkyl; two adjacent ring system substituent groups can be joined together to form a methylenedioxy or ethylenedioxy group.

- 13 -

"Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, pyrrolidonyl, tetrahydrothiophenyl, and the like.

"Heteroaralkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.

"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.

"Acyl" means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.

"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1-naphthoyl.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.

- 14 -

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.

5 "Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.

"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.

10 "Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.

"Alkoxy carbonyl" means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxy carbonyl groups include methoxy carbonyl and ethoxy carbonyl. The bond to the parent moiety is through the carbonyl.

15 "Aryloxy carbonyl" means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxy carbonyl groups include phenoxy carbonyl and naphthoxy carbonyl. The bond to the parent moiety is through the carbonyl.

"Aralkoxy carbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxy carbonyl group is benzyloxy carbonyl. The bond to the parent moiety is through the carbonyl.

"Alkylsulfonyl" means an alkyl-S(O₂)- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.

25 "Arylsulfonyl" means an aryl-S(O₂)- group. The bond to the parent moiety is through the sulfonyl.

The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

30

- 15 -

The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.

It should also be noted that any heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the hydrogen atom to satisfy the valences.

When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene *et al*, *Protective Groups in organic Synthesis* (1991), Wiley, New York.

When any variable (e.g., aryl, heterocycle, R^2 , etc.) occurs more than one time in any constituent or in any of the formulae, its definition on each occurrence is independent of its definition at every other occurrence.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

Prodrugs and solvates of the compounds of the invention are also contemplated herein. The term "prodrug", as employed herein, denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of formula I or II or a salt and/or solvate thereof. A discussion of prodrugs is provided in T. Higuchi and V. Stella, *Pro-drugs as Novel Delivery Systems* (1987) 14 of the A.C.S. Symposium Series, and in *Bioreversible Carriers in Drug Design*, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, both of which are incorporated herein by reference thereto.

"Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable

- 16 -

solvates include ethanولات, methanولات, and the like. "Hydrate" is a solvate wherein the solvent molecule is H₂O.

"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in antagonizing the dopamine receptor and thus producing the desired therapeutic, ameliorative or preventative effect.

The compounds of formulae I and II can form salts, which are also within the scope of this invention. Reference to the compounds of formulae I and II herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when compounds of formulae I and II contain both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the formulae I and II may be formed, for example, by reacting a compounds of formulae I and II with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by S. Berge *et al*, *Journal of Pharmaceutical Sciences* (1977) 66(1) 1-19; P. Gould, *International J. of Pharmaceutics* (1986) 33 201-217; Anderson *et al*, *The Practice of Medicinal Chemistry* (1996), Academic Press, New York; and in *The Orange Book* (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.

- 17 -

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.

All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

Compounds of formulae I and II, and salts and solvates thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.

All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts and solvates of the compounds), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the *IUPAC* 1974 Recommendations. The use of the terms "salt", "solvate", "prodrug" and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrugs of the inventive compounds.

N-oxides can form on a tertiary nitrogen present in an X¹, R or R² substituent, or on =N- in a heteroaryl ring substituent and are included in the compounds of formulae I and II.

For compounds of the invention having at least one asymmetrical carbon atom, all isomers, including diastereomers, enantiomers and rotational isomers are

- 18 -

contemplated as being part of this invention. The invention includes d and l isomers in both pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of a compound of formula I or II.

5 Compounds of formulae I and II can exist in unsolvated and solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for purposes of this invention.

10 A compound of formula I or II may form pharmaceutically acceptable salts with organic and inorganic acids. For example, pyrido-nitrogen atoms may form salts with strong acids, while tertiary amino groups may form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in the art. The salts are
15 prepared by contacting the free base forms with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution, such as dilute aqueous sodium hydroxide, potassium carbonate, ammonia or sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in
20 certain physical properties, such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for purposes of the invention.

25 Another aspect of this invention is a method of treating a patient (e.g., human) having a disease or condition mediated by MCH by administering a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound to the patient.

 A preferred dosage is about 0.001 to 100 mg/kg/day of the formula I or II compound. An especially preferred dosage is about 0.01 to 25 mg/kg/day of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound.

30 Another aspect of this invention is directed to a method of treating obesity comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound.

 Another aspect of this invention is directed to a method for treating metabolic disorders such as obesity and eating disorders such as bulimia and anorexia

- 19 -

comprising administering to a patient a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound.

Another aspect of this invention is directed to a method for treating hyperlipidemia comprising administering to a patient a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound.

Another aspect of this invention is directed to a method for treating cellulite and fat accumulation comprising administering to a patient a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound.

Another aspect of this invention is directed to a method for treating type II diabetes comprising administering to a patient a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound.

In addition to the "direct" effect of the compounds of this invention on the MCH subtype, there are diseases and conditions that will benefit from the weight loss such as insulin resistance, impaired glucose tolerance, Type II Diabetes, hypertension, hyperlipidemia, cardiovascular disease, gall stones, certain cancers, and sleep apnea.


This invention is also directed to pharmaceutical compositions which comprise an amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier therefore.

This invention is also directed to pharmaceutical compositions for the treatment of obesity which comprise an obesity treating amount of a compound of formula I or II, or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier therefore.


Compounds of formulae I and II can be produced by processes known to those skilled in the art using either solution phase or solid phase synthesis as shown in the following reaction schemes, in the preparations and examples below.

Compounds of formulae Ia (where R⁶ is H) and Ib are prepared according to the methods described in scheme 1.

- 20 -





formula Ia



formula Ib


Scheme 1



- 5 Aniline 2 is acylated with bromo acetyl bromide to afford amide 3. Suzuki coupling of amine 4, in which X is a -(C1-C2)alkylene, with an aryl boronic acid gives biaryl amine 5. Nucleophilic displacement of bromide 3 with amine 5 affords the secondary amine 6, which is subsequently coupled to an acid in which n=1 or 2 under standard conditions to give chloride 7. Alternatively, amine 6 is acylated with bromoacetyl bromide to give bromide 7. Nucleophilic displacement of chloride or bromide 7 with the appropriate amine affords the desired di-amide Ib wherein R⁴ is as described previously in the Detailed Descriptions. . Alternatively, the sequence of steps can be changed so that the Suzuki coupling is carried out at the end of the sequence.
- 10

- 21 -


Compounds of formula Ia (where R⁶ is alkyl) and Ic are prepared according to the methods described in Scheme 2.



methyl group is (S), (R) or racemic
formula Ic

5

Scheme 2




Suzuki coupling of 4-bromo-α-methylbenzyl amine **8** (chiral or racemic) with an aryl boronic acid gives biaryl amine **9**. Nucleophilic displacement of bromide **3** with amine **9** affords the secondary amine **10**, which is subsequently coupled to an acid in which n=1 or 2 under standard conditions to give chloride **11**. Alternatively, amine **10** is acylated with bromoacetyl bromide to give bromide **11**. Nucleophilic displacement of chloride or bromide **11** with the appropriate amine affords the desired di-amide **1c** in which R⁴ is as described previously in the Detailed Descriptions.

10

- 22 -

Alternatively, compounds of formulae Ib and Ic (where n=2) can be prepared according to Scheme 3.


Scheme 3



Amine **6** or **10** is acylated with acryloyl chloride in the presence of base such as TEA to give olefin **12**. Addition of the appropriate amine affords the desired di-amide **Ib** or **Ic** in which R⁴ is as described previously in the Detailed Descriptions.

Compounds of this invention of formula II are prepared according to the method shown below in Scheme 4.

Scheme 4




Amine **13** is acylated with an acid halide **14** to provide amide **15**. Alkylation of **15** with an amine gives amine **16**, which in turn can be coupled with acids **17** under

- 23 -

standard conditions. Suzuki coupling of **18** with the appropriate boronic acid affords compounds of type **II**.

The following scheme illustrates the general method employed for synthesis of non-commercially available starting materials used in the above synthetic sequences (scheme 5). Amine **A** is acylated with an anhydride to provide amide **B**. Halogenation of **B** affords aryl halide **C**, which is subsequently deprotected with base to provide halogenated intermediates **D**.



The compounds of formulae **I** and **II** exhibit MCH receptor antagonizing activity, which has been correlated with pharmaceutical activity for treating eating disorders, such as obesity and hyperphagia, and diabetes.

The compounds of formulae **I** and **II** display pharmacological activity in a test procedure designed to demonstrate MCH receptor antagonist activity. The compounds are non-toxic at pharmaceutically therapeutic doses.

Yet another aspect of this invention are combinations of a compound of formula **I** or **II**, or a pharmaceutically acceptable salt of said compound and one or more other compounds as illustrated below.

Accordingly, another aspect of this invention is a method for treating obesity comprising administering to a patient

- an amount of a first compound, said first compound being a formula **I** or **II** compound, or a pharmaceutically acceptable salt of said compound; and
- an amount of at least one more compound, said other compound (b) is selected from an antiobesity and/or anorectic agent such as a β_3 agonist, a

- 24 -

thyromimetic agent, an anorectic agent, and an NPY antagonist wherein the amounts of the (a) and (b) compounds result in a therapeutic effect.

This invention is also directed to a pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising
5 a first compound, said first compound being a formula I or II compound, or a pharmaceutically acceptable salt of said compound; and

at least one other compound selected from an antiobesity and/or anorectic agent such as a β_3 agonist, a thyromimetic agent, an anorectic, and an NPY antagonist; and/or optionally a pharmaceutical carrier, vehicle or diluent.

10 Another aspect of this invention is a kit comprising:

a. an amount of a formula I or II compound, or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form;

15 b. an amount of at least one antiobesity and/or anorectic agent such as a β_3 agonist, a thyromimetic agent, an anorectic agent, or an NPY antagonist and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and

c. means for containing said first and second dosage forms wherein the amounts of the first and second compounds result in a therapeutic effect.

20 Preferred antiobesity and/or anorectic agents (taken singly or in any combination thereof) in the above combination methods, combination compositions and combination kits are: phenylpropanolamine, ephedrine, pseudoephedrine, phentermine, a cholecystokinin-A (hereinafter referred to as CCK-A) agonist, a monoamine reuptake inhibitor (such as sibutramine), a sympathomimetic agent, a
25 serotonergic agent (such as dexfenfluramine or fenfluramine), a dopamine agonist (such as bromocriptine), a melanocyte-stimulating hormone receptor agonist or mimetic, a melanocyte-stimulating hormone analog, a cannabinoid receptor antagonist, a melanin concentrating hormone antagonist, the OB protein (hereinafter referred to as "leptin"), a leptin analog, a leptin receptor agonist, a galanin antagonist
30 or a GI lipase inhibitor or decreaser (such as orlistat). Other anorectic agents include bombesin agonists, dehydroepiandrosterone or analogs thereof, glucocorticoid receptor agonists and antagonists, orexin receptor antagonists, urocortin binding protein antagonists, agonists of the glucagon-like peptide-1 receptor such as Exendin and ciliary neurotrophic factors such as Axokine.

- 25 -

Another aspect of this invention is a method treating diabetes comprising administering to a patient (*e.g.*, a female or male human)

a. an amount of a first compound, said first compound being a formula I or II compound, or a pharmaceutically acceptable salt of said compound; and

5 b. at least one other compound, selected from being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin (including orally bioavailable insulin preparations), an insulin mimetic, metformin, acarbose, a PPAR-gamma ligand such as troglitazone, rosiglitazone, pioglitazone or
10 GW-1929, a sulfonylurea, glipazide, glyburide and chlorpropamide wherein the amounts of the (a) and (b) compounds result in a therapeutic effect.

This invention is also directed to a pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising

a first compound, said first compound being a formula I or II compound, or a
15 pharmaceutically acceptable salt of said compound;

at least one other compound, selected from being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin (including orally bioavailable insulin preparations), an insulin mimetic, metformin,
20 acarbose, a PPAR-gamma ligand such as troglitazone, rosiglitazone, pioglitazone or GW-1929, a sulfonylurea, glipazide, glyburide and chlorpropamide; and optionally a pharmaceutical carrier, vehicle or diluent.

Another aspect of this invention is a kit comprising:

a. an amount of a formula I or II compound, or a pharmaceutically
25 acceptable salt of said compound and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form;

b. at least one other compound, selected from being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin (including orally bioavailable insulin preparations), an insulin mimetic, metformin,
30 acarbose, a PPAR-gamma ligand such as troglitazone, rosiglitazone, pioglitazone or GW-1929, a sulfonylurea, glipazide, glyburide and chlorpropamide and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and

- 26 -

c. means for containing said first and second dosage forms wherein the amounts of the first and second compounds result in a therapeutic effect.

The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 100 mg, preferably from about 1 mg to about 50 mg, more preferably from about 1 mg to about 25 mg, according to the particular application.

The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.

The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 300 mg/day, preferably 1 mg/day to 50 mg/day, in two to four divided doses.

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), *Remington's Pharmaceutical Sciences*, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

- 27 -

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.

Also included are solid form preparations that are intended to be converted,
5 shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type
10 as are conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve
15 the desired purpose.

This invention is also directed to pharmaceutical compositions for the treatment of metabolic disorders such as obesity, and eating disorders such as hyperphagia.

For preparing pharmaceutical compositions from the compounds described by
20 this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets,
25 powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), *Remington's Pharmaceutical Sciences*, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.

30 Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

- 28 -

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.

Also included are solid form preparations that are intended to be converted,
5 shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type
10 as are conventional in the art for this purpose.

The compounds of this invention may also be delivered subcutaneously.

Preferably the compound is administered orally.

The invention disclosed herein is exemplified by the following preparations and examples which should not be construed to limit the scope of the disclosure.
15 Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.

Where NMR data are presented, ^1H spectra were obtained on either a Varian VXR-200 (200 MHz, ^1H), Varian Gemini-300 (300 MHz) or XL-400 (400 MHz) and are reported as ppm down field from Me_4Si with number of protons, multiplicities, and
20 coupling constants in Hertz indicated parenthetically. Where LC/MS data are presented, analyses was performed using an Applied Biosystems API-100 mass spectrometer and Shimadzu SCL-10A LC column: Altech platinum C18, 3 micron, 33mm x 7mm ID; gradient flow: 0 min – 10% CH_3CN , 5 min – 95% CH_3CN , 7 min – 95% CH_3CN , 7.5 min – 10% CH_3CN , 9 min – stop. The retention time and observed
25 parent ion are given.

Compounds useful in this invention are exemplified by the following preparative examples, which should not be construed to limit the scope of the invention. Alternative mechanistic pathways and analogous structures within the scope of the invention would be apparent to those skilled in the art.

30 Starting materials are prepared by known methods and/or methods described in the Preparations.


The following solvents and reagents may be referred to by their abbreviations in parenthesis:

ethyl acetate (EtOAc);
methanol (MeOH);
triethylamine (TEA);
nuclear magnetic resonance spectroscopy (¹H NMR);
liquid chromatography mass spectrometry (LCMS);
high resolution mass spectrometry (HRMS);
milliliters (mL);
millimoles (mmol);
microliters (μL);
grams (g);
milligrams (mg);
room temperature (ambient) about 25°C (rt);
1,2-dimethoxyethane (DME);
ethanol (EtOH);
N,N-dimethylformamide (DMF);
1-hydroxybenzotriazole (HOBt);
1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDCI);
tert-butoxycarbonyl (Boc).

Experimental Examples

The following examples illustrate the preparation of some of the compounds of the invention and are not to be construed as limiting the invention disclosed herein.

EXAMPLE 1



Step 1:

To a stirred solution of 3,5-dichloroaniline (10.4 g, 64.18 mmol) in methylene chloride, cooled to 0 °C, was added bromoacetyl bromide (6.71 mL, 77.02 mmol)

- 30 -

dropwise. The precipitous mixture stirred at 0 °C for 1 h. The reaction mixture was quenched with 10% NaOH and extracted with methylene chloride. The combined extracts were dried over Na₂SO₄ and concentrated to afford 16.21 g (90%) of bromide as a solid.

5 Step 2:

To a stirred solution of 4-bromobenzyl amine hydrochloride (12.2 g, 54.82 mmol) in 250 mL toluene:ethanol:H₂O (3:1:1) was added 3-cyanophenyl boronic acid (16.11 g, 109.65 mmol), Pd(PPh₃)₄ (6.3 g, 5.48 mmol) and Na₂CO₃ (35 g, 330 mmol). The mixture was degassed with N₂, then heated to 100 °C for 24 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over MgSO₄, filtered, concentrated and chromatographed over silica gel (eluting with MeOH/CH₂Cl₂) to yield 7.44 g (65%) of biaryl amine as an oil.

10 Step 3:

To a stirred solution of amine formed in step 2, (3.88 g, 18.65 mmol) and bromide formed in step 1, (2.64 g, 9.32 mmol) in DMF (20 mL) was added K₂CO₃ (3.86 g, 27.98 mmol) and heated to 50 °C for 6 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over Na₂SO₄, concentrated and chromatographed over silica gel (eluting with EtOAc/hexanes) to yield 2.92 g (76%) of an amine.

20 Step 4:

To a stirred solution of amine formed in step 3, (0.41 g, 1.01 mmol) in methylene chloride (3 mL) was added 3-chloropropionic acid (0.22 g, 2.03 mmol) and EDCI (0.38 g, 2.03 mmol) and stirred at rt for 24 h. The reaction mixture was concentrated and used as a crude mixture for step 5.

25 Step 5:

To a stirred solution of chloride formed in step 4, (0.06 g, 0.12 mmol) in pyrrolidine (1 mL) was added K₂CO₃ (0.02 g, 0.12 mmol) and NaI (0.02 g, 0.12 mmol) and heated to 80 °C for 2.5 h. The reaction mixture was diluted with EtOAc, washed with NaHCO₃ solution, dried over MgSO₄, filtered and chromatographed (eluting with EtOH/EtOAc) to yield 0.03 g (51%) amine as a solid.

300 MHz – ¹H NMR (CDCl₃) – 9.08, *8.23 (s, 1H); 7.83 (s, 1H); 7.80-7.76 (m, 1H); 7.66-7.46 (m, 4H); 7.43-7.42 (d, 2H); 7.33-7.26 (d, 2H); 7.05 (s, 1H); 4.78, *4.73 (s, 2H); *4.16, 4.13 (s, 2H); 2.93-2.77 (m, 2H); 2.75-2.53 (m, 2H); 1.81-1.75 (m, 4H).

35 Data provided is for a mixture of rotamers, * indicates the minor split peak.

HRMS (M+H⁺) 535.1663

MCH Ki = 21 nm

- 31 -

Further, listed below is the experimental procedure for Example 9 in Table 1, which was also prepared according to Scheme 1.

Step 1:

To a stirred solution of 3,5-dichloroaniline (10.4 g, 64.18 mmol) in methylene chloride, cooled to 0 °C, was added bromoacetyl bromide (6.71 mL, 77.02 mmol) dropwise. The precipitous mixture stirred at 0 °C for 1 h. The reaction mixture was quenched with 10% NaOH and extracted with methylene chloride. The combined extracts were dried over Na₂SO₄ and concentrated to afford 16.21 g (90%) of bromide as a solid.

Step 2:

To a stirred solution of 4-bromophenyl ethyl amine hydrochloride (12.6 g, 63.00 mmol) in 250 mL toluene:ethanol:H₂O (3:1:1) was added 3-cyanophenyl boronic acid (13.71 g, 109.65 mmol), Pd(PPh₃)₄ (7.2 g, 6.3 mmol) and Na₂CO₃ (33 g, 330 mmol). The mixture was degassed with N₂, then heated to 100 °C for 24 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over MgSO₄, filtered, concentrated and chromatographed over silica gel (eluting with MeOH/CH₂Cl₂) to yield 8.2 g (58%) of biaryl amine as an oil.

Step 3:

To a stirred solution of amine formed in step 2, (2.0 g, 9.0 mmol) and bromide formed in step 1, (1.69 g, 6.00 mmol) in CH₃CN (30 mL) was added K₂CO₃ (1.65 g, 12.0 mmol) and heated to 50 °C for 6 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over Na₂SO₄, concentrated and chromatographed over silica gel (eluting with EtOAc/hexanes) to yield 1.6 g (64%) of an amine.

Step 4:

To a stirred solution of amine formed in step 3, (0.54 g, 1.27 mmol) in methylene chloride (10 mL) was added acryloyl chloride (0.114 g, 1.91 mmol) and triethyl amine (0.266 mL, 1.99 mmol) and stirred at rt for 24 h. The reaction mixture was diluted with methylene chloride, washed with water, dried over MgSO₄, filtered, concentrated and used in the next step with out purification.

Step 5:

To a stirred solution of olefin (0.030, 0.62 mmol) from step 4 in methylene chloride (1 mL) was added pyrrolidine (0.1 mL) and stirred at rt for 24 h. The reaction mixture was concentrated and purified to yield 0.02g (59%) of an amine.

- 32 -




300 MHz – ^1H NMR (CDCl_3) – 9.28 (s, 1H); 7.83 (s, 1H); 7.80-7.76 (m, 1H); 7.66-7.46 (m, 4H); 7.43-7.42 (d, 2H); 7.33-7.26 (d, 2H); 7.05 (s, 1H); 4.42, *4.52 (s, 2H); *4.16, 4.13 (s, 2H); 3.73 (m, 2 H), 3.44-2.77 (m, 2H); 2.75-2.53 (m, 2H); 1.81-1.75 (m, 4H). Data provided is for a mixture of rotamers, * indicates the minor split peak.

HRMS ($\text{M}+\text{H}^+$) 549.1835

EXAMPLES 2--39


Employing preparative procedures similar to those described in Example 1 and Example 9, the following compounds were prepared:

Table 1

Ex.	Structure	HRMS	MCH Ki (nm)
2		551.1612	3.7
3		535.1919	3.7
4		519.1957	5.3

- 33 -


5



569.2174

6.7


6



565.1617

7.2


7



549.1830

9.3


8



549.1835

9.5


9



549.1835

10.0

10




585.1872

11.0

- 34 -


11



553.2236

11.7


12



565.1782

12.0


13



550.1768

13.0


14



551.1607

15.0


15



535.1658

19.0

16




537.1816

24.0

- 35 -


17



569.1936

25.0


18



537.1454

27.0


19



553.2230

28.0


20



535.1662

32.0


21



521.1500

35.0


22



495.1348

36.0

23




549.1835

37.0

- 36 -


24



561.1830

40.0


25



481.1198

52.0


26



565.1783

56.0


27



537.1452

61.0


28



564.1933

63.0

29




539.2065

72.0

- 37 -


30



549.1817

73.0


31



592.1875

82.0


32



509.1504


90.0

33




551.1612

34



503.2259


35



578.2080

- 38 -


36



565.1777

8


37



563.1975


9

38



579.1921


39



564.1940

Examples 40-60 are prepared according to Scheme 2 and 3

- 39 -

EXAMPLE 40

Step 1:

To a stirred solution of 3,5-dichloroaniline (10.4 g, 64.18 mmol) in methylene chloride, cooled to 0 °C, was added bromoacetyl bromide (6.71 mL, 77.02 mmol) dropwise. The precipitous mixture stirred at 0 °C for 1 h. The reaction mixture was quenched with 10% NaOH and extracted with methylene chloride. The combined extracts were dried over Na₂SO₄ and concentrated to afford 16.21 g (90%) of bromide as a solid.

Step 2:

To a stirred solution of 4-bromo- α -methylbenzyl amine (1.0 mL, 6.98 mmol) in 25 mL toluene:ethanol:H₂O (3:1:1) was added 3-cyanophenyl boronic acid (2.05 g, 13.96 mmol), Pd(PPh₃)₄ (0.81 g, 0.698 mmol) and Na₂CO₃ (7.39 g, 69.8 mmol). The mixture was degassed with N₂, then heated to 100 °C for 24 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over MgSO₄, filtered, concentrated and chromatographed over silica gel (eluting with EtOH/EtOAc) to yield 1.14 g (73%) of biaryl amine as an oil.

Step 3:

To a stirred solution of amine formed in step 2, (0.51 g, 2.28 mmol) and bromide formed in step 1, (0.32 g, 1.14 mmol) in CH₃CN (8 mL) was added K₂CO₃ (0.47 g, 3.42 mmol) and heated to 50 °C for 6 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over Na₂SO₄, concentrated and chromatographed over silica gel (eluting with EtOAc/hexanes) to yield 0.34 g (35%) of an amine.

Step 4:

To a stirred solution of amine formed in step 3, (0.20 g, 0.48 mmol) in methylene chloride (3 mL) was added chloroacetic acid (0.09 g, 0.97 mmol) and EDCI (0.18 g, 0.97 mmol) and stirred at rt for 24 h. The reaction mixture was concentrated and used as a crude mixture for step 5.

Step 5:

To a stirred solution of chloride formed in step 4, (0.48 mmol) in CH₃CN (3 mL) was added pyrrolidine (0.2 mL, 2.41 mmol), K₂CO₃ (0.33 g, 2.41 mmol) and NaI (0.14

- 40 -

g, 0.96 mmol) and heated to 80 °C for 24 h. The reaction mixture was diluted with EtOAc, washed with NaHCO₃ solution, dried over MgSO₄, filtered and chromatographed (eluting with EtOH/ EtOAc) to yield 0.12 g (47%) amine as a solid.

300 MHz – ¹H NMR (CDCl₃) - *9.23, 7.18 (s, 1H); 7.82-7.77 (m, 2H); 7.67-7.44 (m, 6H); 7.40-7.37 (d, 2H); 7.01 (s, 1H); *6.11-6.08, 5.66-5.64 (m, 1H); *4.08, 3.70 (s, 2H); 3.59, *3.47 (s, 2H); *2.90-2.88, 2.69-2.67 (m, 4H); 1.89-1.58 (m, 4H), 1.27-1.21 (t, 3H). Data provided is for a mixture of rotamers, * indicates the minor split peak.





HRMS (M+H⁺) 535.1658

MCH Ki = 21 nm

EXAMPLES 41-60


Employing preparative procedures similar to those described in Example 39, the following compounds were prepared:

Table 2

Ex.	Structure	HRMS	Ki (MCH)
41		565.1782	12.0
42		551.1607	16.0
43		565.1783	18.0
44		563.1986	18.0

- 41 -


45



537.1824

22.0


46



549.1819

22.0


47



565.1773

23.0


48



549.1825

28.0


49



551.1617

31.0


50



551.1987

34.0

51




523.1658

45.0

- 42 -


52



563.1986

67.0


53



509.1519


78.0

54




585.1828

55




563.1981

56



549.1835


57



563.1621


- 43 -

58




561.1829

59



577.1777


60



575.1989

Examples 61-65 were prepared according to Scheme 5.

Example 61



5

Step 1:

A solution of 3,5-dichloroaniline (1.5 g, 9.26 mmol) in CH_2Cl_2 (100 mL) at 0 °C was treated with bromoacetyl bromide (1.05 mL, 12.0 mmol). After 45 min, the

- 44 -

reaction mixture was washed with 1N NaOH, H₂O, dried and concentrated in vacuo to provide crude bromide (2.66 g) as a white solid.

Step 2:

A solution of crude bromide (300 mg, 1.06 mmol) in CH₃CN (10 mL) was treated with 1-(3-aminopropyl)pyrrolidine (280 μ L, 2.20 mmol) and heated to 60 °C. After 7 h, the reaction mixture was cooled to ambient temperature, diluted with saturated aqueous NH₄Cl and extracted with EtOAc (3x). The combined organic extracts were washed with saturated aqueous NaHCO₃, brine, dried and concentrated in vacuo. The crude product was dissolved in dichloroethane (6 mL) and treated with 4-iodophenylacetic acid (160 mg, 0.610 mmol) followed by diisopropylethyl amine (348 μ L, 2.00 mmol). EDCI (156 mg, 0.790 mmol) and HOBT (107 mg, 0.790 mmol) were added and the reaction mixture was heated to 60 °C. After 5 h, the reaction mixture was cooled to ambient temperature, diluted with saturated aqueous NaHCO₃, and extracted with CH₂Cl₂ (3x). The combined organic extracts were dried and concentrated in vacuo. Flash chromatography (2% MeOH/ CH₂Cl₂ \rightarrow 95:4.5:0.5 CH₂Cl₂, MeOH, NH₄OH gradient) afforded the iodoaryl amide (220 mg, 63% over 2 steps) as a yellow oil.

Step 3:

A solution of aryl iodide (100 mg, 0.174 mmol) in DME/H₂O (2:1, 3 mL) was treated with sodium carbonate (28 mg, 0.261 mmol) followed by 3-cyanophenylboronic acid (38 mg, 0.261 mmol). Pd(dppf)Cl₂ (16 mg, 0.020 mmol) was added and the reaction mixture was heated to 80 °C. After 4 h, the reaction mixture was cooled to ambient temperature, diluted with saturated aqueous NaHCO₃, and extracted with EtOAc (2x). The combined organic extracts were dried and concentrated in vacuo. Preparative thin layer chromatography (10% MeOH/CH₂Cl₂) furnished the biaryl amide (32.4 mg, 34%) as a clear oil: ¹H NMR (300 MHz, CDCl₃) δ 9.16 (s, 1 H), 7.84 (s, 1 H), 7.78 (d, *J* = 7.8 Hz, 1 H), 7.62 (d, *J* = 7.5 Hz, 1 H), 7.56-7.50 (m, 3 H), 7.39-7.35 (m, 4 H), 7.02 (s, 1 H), 4.12 (s, 2 H), 3.97 (s, 2 H), 3.58 (t, *J* = 6.0 Hz, 2 H), 2.48-2.43 (m, 6 H), 1.85-1.78 (m, 6 H). LCMS: 549.1, *rt.* = 5.01 min (*M*+1), HRMS *m/z* 549.1831 [(*M*+H)⁺].





MCH Ki = 62 nM

- 45 -

EXAMPLES 62-65

Employing preparative procedures similar to those described in Example 61, the following compounds were prepared:

Table 3

Ex.	Structure	HRMS	Ki (MCH)
62		519.1967	
63		553.2236	
64		521.1515	
65		526.1669	

MCH receptor binding assay:

Membranes from CHO cells expressing the MCH receptor were prepared by lysing cells with 5 mM HEPES for 15 min at 4C. Cell lysates were centrifuged (12.5000 x g, 15 min) and the pellet was re-suspended in 5 mM HEPES. For each 96-well plate (Microlite, Dynex Technologies), 1 mg of cell membranes were

- 46 -


incubated with 10 mg of wheat germ agglutinin SPA beads (Amersham) for 5 min at 4 C in a volume of 10 ml of binding buffer (25 mM HEPES, 10 mM MgCl_2 , 10 mM NaCl, 5 mM MnCl_2 , 0.1% BSA). The membrane/bead mixture was centrifuged (1500 x g, 3.5 min), the supernatant was aspirated, and the pellet was re-suspended in 10 ml binding buffer. The centrifugation, aspiration and re-suspension were then repeated. The membrane/bead mixture (100 μl) was then added to 96-well plates containing 50 μl of 500 pM [^{125}I]-MCH (NEN) and 50 ml of the appropriate concentration of compound (4X the desired final concentration). Nonspecific binding was determined by including 1 μM MCH in the binding reaction. The binding reaction was incubated at room temperature for 2 h. Plates were then analyzed in a TOPCOUNT microplate scintillation counter (Packard). Data was analyzed and K_i values were determined using GraphPad Prim.

For the compounds of this invention, a range of MCH receptor binding activity (K_i values) of from about 3 nM to about 1500 nM was observed. Compounds of this invention have a binding activity in the range of from about 3 nM to about 1000 nM.

While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall with the spirit and scope of the present invention.

WHAT IS CLAIMED:

- 5 1. A compound of formula I:



formula I

or a pharmaceutically acceptable salt or solvate of said compound, wherein:

10 X is a single bond, -C-, -CH- or alkylene, and when X is a single bond, R⁶ is absent and the carbon atom marked 1 is directly attached to N of N-Y;

Y is a single bond, -C-, -CH- or alkylene, and when Y is a single bond, R⁵ is absent and the carbon atom marked 7 is directly attached to N of N-X;


15 R¹ is aryl or heteroaryl, wherein each of said aryl or heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CN, CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

20 R² is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

25 R³ is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R⁴ is selected from the group consisting of -alkylene-N(R⁷)₂, -N(H)alkylene-N(R⁷)₂, -O-alkylene-N(R⁷)₂,

- 48 -



wherein each R^7 in said $\text{---N(R}^7\text{)}_2$, can be the same or different each R^7 is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R^7 can be joined together and with the nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring;

n is 0 or 1;

p is 0 to 5 and when p is >1 , the number of p moieties can be the same or different;

R^5 is H or 1 or 2 substituents independently selected from alkyl or cycloalkyl;

R^6 is H or 1 or 2 substituents independently selected from alkyl or cycloalkyl;

and


R^8 is H, OH; alkoxy, alkyl, cycloalkyl, aryl, ---N(H)R^7 , ---N(H)C(O)alkyl , ---N(H)C(O)aryl , $\text{---N(H)C(O)N(H)alkyl}$, $\text{---N(H)C(O)N(H)aryl}$, $\text{---N(H)S(O}_2\text{)alkyl}$ or

- 49 -

-N(H)S(O₂)aryl;

with the proviso that the carbons shown marked 1 and 6 on the aromatic ring, along with X-R⁶, can optionally form a 4 to 8 membered ring system.

5 2. The compound of claim 1 of formula Ia:



formula Ia

or a pharmaceutically acceptable salt or solvate of said compound, wherein:

q is 0 to 5 and when q is >1, the number of q moieties can be the same or
10 different;

X is -CH- or alkylene;

Y is a CH₂;


R² is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be
unsubstituted or optionally independently substituted with one or more moieties which
15 can be the same or different, each moiety being independently selected from the
group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy,
alkoxy and OH;

R³ is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be
unsubstituted or optionally independently substituted with one or more moieties which
20 can be the same or different, each moiety being independently selected from the
group consisting of CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl,
haloalkoxy, alkoxy and OH;

R⁴ is -alkylene-N(R⁷)₂, wherein the two R⁷ moieties can be the same or
different, each R⁷ is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or
25 cycloalkyl can be unsubstituted or optionally independently substituted with one or
more moieties which can be the same or different, each moiety being independently
selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl,
haloalkyl, haloalkoxy, alkoxy and OH; or each R⁷ can be joined together and with the

- 50 -

nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring, or R^4 is selected from




R^5 and R^6 can be the same or different, and are independently H or alkyl;

- 5 R^8 is H, OH, alkoxy, alkyl, cycloalkyl, aryl, ---N(H)R^7 , ---N(H)C(O)alkyl , $\text{---N(H)C(O)N(H)alkyl}$ or $\text{---N(H)S(O}_2\text{)alkyl}$;
and

R^9 is alkyl, F, Cl, Br, I, NO_2 , C(O)NH_2 , C(O)N(H)R or N(H)C(O)R , wherein R is alkyl, OCF_3 , CF_3 or CN.

10

3. The compound of claim 2 wherein R^9 is a 3 or 4-substituted aryl.
4. The compound of claim 2 wherein R^9 is a 3 --cyano substituted aryl.
- 15 5. The compound of claim 1 of formula Ib:



formula Ib

or a pharmaceutically acceptable salt or solvate of said compound, wherein:

X is an alkylene group;

R^1 is 3-cyanophenyl;

R^2 is H;


R^3 is a phenyl, wherein said phenyl is substituted with one or more moieties which can be the same or different, each moiety being independently selected from

20

- 51 -

the group consisting of CF_3 , halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;


R^4 is $\text{—alkylene—N(R}^7\text{)}_2$, wherein the two R^7 moieties can be the same or different, each R^7 is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R^7 can be joined together and with the nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring; or R^4 is selected from



and

R^8 is H, alkyl, cycloalkyl, aryl, —N(H)alkyl , —N(H)aryl , OH, alkoxy, —N(H)C(O)alkyl , $\text{—N(H)C(O)N(H)alkyl}$ or $\text{—N(H)S(O}_2\text{)alkyl}$.

6. The compound of claim 1 of formula 1c:



methyl group is (S), (R) or racemic

formula 1c

or a pharmaceutically acceptable salt or solvate of said compound, wherein:


R^1 is 3-cyanophenyl;

R^2 is H;

- 52 -

R^3 is a phenyl, wherein said phenyl is substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF_3 , halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

- 5 R^4 is $-\text{alkylene}-N(R^7)_2$, wherein the two R^7 moieties can be the same or different, each R^7 is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R^7 can be joined together and with the nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring; or R^4 is selected from





15 and













R^8 is H, alkyl, cycloalkyl, aryl, $-\text{N}(\text{H})\text{alkyl}$, $-\text{N}(\text{H})\text{aryl}$, OH, alkoxy, $-\text{N}(\text{H})\text{C}(\text{O})\text{alkyl}$, $-\text{N}(\text{H})\text{C}(\text{O})\text{N}(\text{H})\text{alkyl}$ or $-\text{N}(\text{H})\text{S}(\text{O}_2)\text{alkyl}$.

7. A compound of claim 1 selected from the group consisting of:













20











- 53 -







- 54 -



- 55 -









- 56 -















or a pharmaceutically acceptable salt or solvate of said compound .



5 8. The compound of claim 1 selected from the group consisting of



- 57 -




- 58 -




or a pharmaceutically acceptable salt or solvate of said compound.

- 5 9. The compound of claim 1 of the formula



or a pharmaceutically acceptable salt or solvate of said compound.


- 10 10. The compound of claim 1 of the formula



or a pharmaceutically acceptable salt or solvate of said compound.


- 15 11. The compound of claim 1 of the formula

- 59 -



or a pharmaceutically acceptable salt or solvate of said compound.

12. A compound of formula II:



formula II

or a pharmaceutically acceptable salt or solvate of said compound, wherein:

Y is a single bond, -C-, -CH- or alkylene, and when Y is a single bond, R⁵ is absent and the carbon atom marked 7 is directly attached to N of N-X;

Z is a single bond, -C-, -CH- or alkylene, and when Z is a single bond, R⁶ is absent and the carbon atom marked 1 is directly attached to the carbon atom marked 8;

R¹ is aryl or heteroaryl, wherein each of said aryl or heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CN, CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R² is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;


- 60 -

R^3 is H, alkyl, aryl or aralkyl wherein each of said aryl or aralkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF_3 , halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R^5 is H or 1 or 2 substituents independently selected from alkyl or cycloalkyl;

R^6 is H or 1 or 2 substituents independently selected from alkyl or cycloalkyl;

R^{10} is selected from the group consisting -alkylene(R^7)₂,



and

n is 0 or 1;

p is 0 to 5 and when p is >1, the number of p moieties can be the same or different;


and

R^8 is H, OH, alkoxy, alkyl, cycloalkyl, aryl, -N(H) R^7 , -N(H)C(O)alkyl, -N(H)C(O)aryl, -N(H)C(O)N(H)alkyl, -N(H)C(O)N(H)aryl, -N(H)S(O₂)alkyl or -N(H)S(O₂)aryl;

- 61 -

with the proviso that the carbons shown marked 1 and 6 on the aromatic ring, along with X-R⁶, can optionally form a 4 to 8 membered ring system.

13. The compound of claim 12 being formula IIa:



formula IIa

or a pharmaceutically acceptable salt or solvate of said compound, wherein:

R¹ is 3-cyanophenyl;




R² is H;

R³ is a phenyl, wherein said phenyl is substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of CF₃, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH;

R⁸ is H, OH, alkyl, cycloalkyl, aryl, -N(H)alkyl, -N(H)aryl, -N(H)C(O)alkyl, N(H)C(O)N(H)alkyl or -N(H)S(O₂)alkyl;

and

R¹⁰ is selected from the group consisting -alkylene(R⁷)₂,




wherein the two R⁷ moieties can be the same or different, each R⁷ is H, alkyl, cycloalkyl or aryl, wherein each of said alkyl, aryl or cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group

- 62 -

consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy and OH; or each R⁷ can be joined together and with the nitrogen to which they are attached to form a 3 to 7-membered heterocyclyl ring.

- 5 14. A compound of claim 12 selected from the group consisting of:



or a pharmaceutically acceptable salt or solvate of said compound.

- 10 15. A method of treating a metabolic disorder, eating disorder or diabetes comprising administering an effective amount of a compound of claim 1 to a patient in need of such treatment.
- 15 16. A method of treating a metabolic disorder, eating disorder or diabetes comprising administering an effective amount of a compound of claim 12 to a patient in need of such treatment.
17. The method of claim 15 wherein said eating disorder is hyperphagia.

- 63 -

18. The method of claim 16 wherein said eating disorder is hyperphagia.

19. The method of claim 15 wherein said metabolic disorder is obesity.

5 20. The method of claim 16 wherein said metabolic disorder is obesity.

21. A method of treating disorders associated with obesity comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound.

10

22. A method of treating disorders associated with obesity comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 12 or a pharmaceutically acceptable salt of said compound.

15 23. The method of claim 21 wherein said disorders associated with obesity are type II diabetes, insulin resistance, hyperlipidemia and hypertension.

24. The method of claim 22 wherein said disorders associated with obesity are type II diabetes, insulin resistance, hyperlipidemia and hypertension.

20

25. A method of treating an eating disorder which comprises administering to a patient in need of such treatment

an amount of a first compound, said first compound being a compound of claim 1, or a pharmaceutically acceptable salt of said compound;

25 an amount of at least one more compound, said other compound (b) is selected from an antiobesity and/or anorectic agent such as a β_3 agonist, a thyromimetic agent, an anorectic agent, and an NPY antagonist;

wherein the amounts of the (a) and (b) compounds result in a therapeutic effect.

30

26. A method of treating an eating disorder which comprises administering to a patient in need of such treatment

- 64 -

an amount of a first compound, said first compound being a compound of claim 12, or a pharmaceutically acceptable salt of said compound;

an amount of at least one more compound, said other compound (b) is selected from an antiobesity and/or anorectic agent such as a β_3 agonist, a thyromimetic agent, an anorectic agent, and an NPY antagonist;

wherein the amounts of the (a) and (b) compounds result in a therapeutic effect.

27. A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 1, or a pharmaceutically acceptable salt of said compound;

an amount of at least one more compound, said other compound (b) is selected from an antiobesity and/or anorectic agent such as a β_3 agonist, a thyromimetic agent, an anorectic agent, and an NPY antagonist; and

a pharmaceutically acceptable carrier

28. A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 12, or a pharmaceutically acceptable salt of said compound;

an amount of at least one more compound, said other compound (b) is selected from an antiobesity and/or anorectic agent such as a β_3 agonist, a thyromimetic agent, an anorectic agent, and an NPY antagonist; and

a pharmaceutically acceptable carrier

29. A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 1, or a pharmaceutically acceptable salt of said compound;

at least one other compound, selected from being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin

- 65 -

(including orally bioavailable insulin preparations), an insulin mimetic, metformin, acarbose, a PPAR-gamma ligand such as troglitazone, rosiglitazone, pioglitazone or GW-1929, a sulfonylurea, glipazide, glyburide and chlorpropamide; and a pharmaceutically acceptable carrier.

5

30. A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 12, or a pharmaceutically acceptable salt of said compound;

10

at least one other compound, selected from being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin (including orally bioavailable insulin preparations), an insulin mimetic, metformin, acarbose, a PPAR-gamma ligand such as troglitazone, rosiglitazone, pioglitazone or GW-1929, a sulfonylurea, glipazide, glyburide and chlorpropamide; and a pharmaceutically acceptable carrier.

15

20

31. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in combination with at least one pharmaceutically acceptable carrier.

25

32. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 12 in combination with at least one pharmaceutically acceptable carrier.

33. A process for making a pharmaceutical composition comprising combining at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/33869

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/277 A61K31/4453 A61K31/4015 A61K31/40 C07D295/14
C07D295/12 C07D207/12 C07D205/04 C07K5/06 C07K5/02
C07C255/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D C07K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 02 057233 A (SCHERING CORP) 25 July 2002 (2002-07-25) the whole document	1-33
E	WO 02 083134 A (PHARMACOEPIA INC) 24 October 2002 (2002-10-24) the whole document	1-33
A	EP 1 219 294 A (CHOH NOBUO ;KATO KANEYOSHI (JP); MORI MASAOKI (JP); SHIMOMURA YUKI) 29 March 2001 (2001-03-29) the whole document & WO 01 21169 A (TAKEDA CHEMICAL INDUSTRIES, LTD.) 29 March 2001 (2001-03-29)	1-33

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 January 2003

Date of mailing of the international search report

23/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Von Daacke, A

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1 and 12 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds according to Claims 1 and 12 wherein R1 denotes phenyl as defined in Claim 2. It should be noted that definitions R4 or R10 including e.g. (C0-C3) are unclear. The related definitions have been interpreted in view of the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/33869

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 15-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/33869

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02057233	A	25-07-2002	WO 02057233 A1	25-07-2002
WO 02083134	A	24-10-2002	WO 02083134 A1	24-10-2002
EP 1219294	A	03-07-2002	AU 7315800 A	24-04-2001
			EP 1219294 A1	03-07-2002
			WO 0121169 A1	29-03-2001
			JP 2002097138 A	02-04-2002